Arpana Gupta, PhD, G. Oppenheimer Center for Neurobiology of Stress and Resilience, is conducting a study on the effects of stress and discrimination in Mexican and Filipina women.
You may be eligible if you:
MUST be of 100 percent Mexican or 100 percent Filipina ancestry
Study participation consists of:
Compensation:
For more information: Call 310-825-7206
Protocol ID:IRB#20-002326 UCLA IRB Approved End Date: 12/2025 Committee: Medical IRB 3
Arpana Gupta, PhD, G. Oppenheimer Center for Neurobiology of Stress and Resilience, is conducting a study comparing women with high and women with low stress.
You may be eligible if you:
Study participation consists of:
Compensation:
For more information: Call Allison at 310-825-7206
Protocol ID:IRB#20-001921 UCLA IRB Approved End Date: 12/2022 Committee: Medical IRB 3
Emeran A. Mayer, MD, director of the G. Oppenheimer Center for Neurobiology of Stress and Resilience, is conducting a study to test the effect of cognitive behavioral therapy (CBT) on the brain and gut in irritable bowel syndrome (IBS).
You may be eligible if you:
Some details:
Compensation:
For more information: Call 310-206-1719
Sex related differences in the effect of cognitive behavioral therapy (CBT) on emotional arousal and salience circuits and the role of the gut microbiome Project 3 Protocol ID:IRB#20-001118 UCLA IRB Approved Approval Date: 1/22/2021 Committee: Medical IRB 3
Berkeley Limketkai, MD, PhD, director of clinical research for the Center for Inflammatory Bowel Diseases, in partnership with the Center for Human Nutrition, is conducting a trial of a UCLA-designed diet for Crohn’s disease.
You may be eligible if you:
Some details:
Compensation:
For more information: 855-IBD-UCLA / 855-423-8252 or [email protected]
Study of dietary composition in Crohn's disease, IRB#20-001120 UCLA IRB Approval Date: Through 4/7/22, Committee: Medical IRB 3, PI: Li
IB-Stim is a non-invasive device that works by sending subtle electrical impulses into cranial nerve branches in the ear. This stimulation then targets brain regions involved in processing pain. The IB-Stim has already been FDA approved for treating functional abdominal pain associated with IBS in children but not FDA approved in adults.
Participants must be:
Participation consists of :
Compensation:
To learn more about participating in this study, please contact Dr. Adrienne Lenhart at [email protected]
This study is conducted by Lin Chang, MD, co-director of the G. Oppenheimer Center for Neurobiology of Stress and Resilience.
Protocol ID: IRB#19-001796 UCLA IRB Approval Date: 7/8/2021 Through: 7/7/2022 Committee: Medical IRB
Dr. Berkeley Limketkai, director of clinical research for the Center for Inflammatory Bowel Diseases, is conducting a research study to better understand the relationship between the diet and IBD and to help guide us on where to focus the next steps of research to provide better dietary recommendations and improve the care of IBD.
Participants must be:
Participation involves:
For more information: 855-IBD-UCLA / 855-423-8252 or [email protected]
UCLA IRB Approved IRB# 19-001299 Committee: Medical IRB 1 Approved / Expiration Date 3/17/22
The purpose of this registry study is to learn more about IBD, how doctors treat IBD, how well medications and other treatments work, the safety of those treatments, and to improve the care and outcomes of people with IBD. Approximately 1,000 men and women ages 18 years and older with a diagnosis of IBD in the U.S. are expected to participate in the first year with no defined upper limit on total enrollment after year one. Non-interventional Corrona Registry research programs are coordinated efforts to collect information directly from physicians and patients with IBD. Findings from CorEvitas Registries will help providers improve the treatment options for these health conditions.
Participants must be:
Compensation:
This study is conducted by Dr. Jenny Sauk with the Center for Inflammatory Bowel Diseases. For further details please contact Xiaoxiao Yin at [email protected].
UCLA IRB Approved IRB# 17-001324 Approval Date: 3/30/2020 through 1/10/2023.
